{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:24:39Z","timestamp":1740140679205,"version":"3.37.3"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":1655,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are limited real-world data on health care resource utilization (HCRU) among advanced melanoma patients. The objective of this study was to describe HCRU and health care costs associated with the management of advanced melanoma patients receiving ipilimumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective multinational, observational study included advanced melanoma patients from Australia, Germany, Italy, and Spain who had received at least 1 dose of ipilimumab. Data extracted from medical charts included inpatient admissions, outpatient visits, surgical procedures, laboratory investigations, radiation therapy, imaging studies, and concomitant medications. Cost estimates were based on unit costs from country-specific standard reimbursement sources. Subgroup analyses were performed for BRAF mutation status and ipilimumab refractory patients, who had disease progression within 24 weeks of their last dose of ipilimumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean age of 362 enrolled patients was 60.6 years (standard deviation [SD] 14.4). During a median follow-up period of 30.2 weeks, 57% of patients were admitted to hospital and 16% underwent surgery. Health care resource utilization rates varied substantially across countries and were highest in Germany. Concomitant medications to treat adverse events were commonly used. Subgroup analyses showed higher utilization rates among ipilimumab refractory and BRAF mutant patients. Mean weekly total costs associated with HCRU were lower in the pre-progression period (\u20ac107; 95% confidence interval (CI): 79\u2013145) than in the post-progression period (\u20ac216; 95% CI: 180\u2013259).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Health care resource utilization pattern and associated costs among patients treated with ipilimumab varied greatly among countries and between pre- and post-progression periods. There is a high economic burden associated with ipilimumab refractory melanoma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0272","type":"journal-article","created":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T00:10:10Z","timestamp":1495239010000},"page":"951-962","source":"Crossref","is-referenced-by-count":14,"title":["Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)"],"prefix":"10.1093","volume":"22","author":[{"given":"Grant A.","family":"McArthur","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre, East Melbourne, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[{"name":"Elbe-Klinikum Buxtehude, Buxtehude, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[{"name":"Hospital Clinic Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Banos Hernaez","sequence":"additional","affiliation":[{"name":"Mapi, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kaskel","sequence":"additional","affiliation":[{"name":"MSD Sharp & Dohme GmbH, Haar, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Weichenthal","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts-Hautklinik Kiel, Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reshma","family":"Shinde","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendall","family":"Stevinson","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"2021122508150253600_onco12126-bib-0001","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"2021122508150253600_onco12126-bib-0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjd.12492","article-title":"Emerging trends in the epidemiology of melanoma","volume":"170","author":"Nikolaou","year":"2014","journal-title":"Br J Dermatol"},{"key":"2021122508150253600_onco12126-bib-0003","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122508150253600_onco12126-bib-0004","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2021122508150253600_onco12126-bib-0005","doi-asserted-by":"crossref","first-page":"ii86","DOI":"10.1093\/annonc\/mdn100","article-title":"Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"19","author":"Dummer","year":"2008","journal-title":"Ann Oncol"},{"year":"2013","author":"Margolin","key":"2021122508150253600_onco12126-bib-0006"},{"year":"2013","author":"Patt","key":"2021122508150253600_onco12126-bib-0007"},{"key":"2021122508150253600_onco12126-bib-0008","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122508150253600_onco12126-bib-0009","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4161\/cc.4.10.2026","article-title":"Analysis of BRAF mutation in primary and metastatic melanoma","volume":"4","author":"Libra","year":"2005","journal-title":"Cell Cycle"},{"key":"2021122508150253600_onco12126-bib-0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajco.12200","article-title":"The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation","volume":"10","author":"Brown","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"2021122508150253600_onco12126-bib-0011","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ejca.2012.03.003","article-title":"Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)","volume":"48","author":"Johnston","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021122508150253600_onco12126-bib-0012","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1185\/03007995.2015.1062356","article-title":"Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting","volume":"31","author":"Toy","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"2021122508150253600_onco12126-bib-0013","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4236\/jct.2015.610091","article-title":"Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab","volume":"6","author":"Tarhini","year":"2015","journal-title":"Journal of Cancer Therapy"},{"year":"2014","author":"Tarhini","key":"2021122508150253600_onco12126-bib-0014"},{"key":"2021122508150253600_onco12126-bib-0015","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0016"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0017"},{"key":"2021122508150253600_onco12126-bib-0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","article-title":"Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: The ISPOR Drug Cost Task Force report\u2013Part I","volume":"13","author":"Hay","year":"2010","journal-title":"Value Health"},{"key":"2021122508150253600_onco12126-bib-0019","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1479-5876-12-116","article-title":"Clinical experience with ipilimumab 3 mg\/kg: Real-world efficacy and safety data from an expanded access programme cohort","volume":"12","author":"Ascierto","year":"2014","journal-title":"J Transl Med"},{"key":"2021122508150253600_onco12126-bib-0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1524-4733.2003.00242.x","article-title":"A checklist for retrospective database studies\u2013report of the ISPOR Task Force on Retrospective Databases","volume":"6","author":"Motheral","year":"2003","journal-title":"Value Health"},{"year":"2014","key":"2021122508150253600_onco12126-bib-0021"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0022"},{"key":"2021122508150253600_onco12126-bib-0023","first-page":"53","article-title":"Calculation of standardised unit costs from a societal perspective for health economic evaluation[in German]","volume":"77","author":"Bock","year":"2015","journal-title":"Gesundheitswesen"},{"key":"2021122508150253600_onco12126-bib-0024","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1756-9966-31-91","article-title":"The cost of unresectable stage III or stage IV melanoma in Italy","volume":"31","author":"Maio","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"year":"2015","key":"2021122508150253600_onco12126-bib-0025"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0026"},{"key":"2021122508150253600_onco12126-bib-0027"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0028"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0029"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0030"},{"year":"2015","key":"2021122508150253600_onco12126-bib-0031"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0032"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0033"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0034"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0035"},{"year":"2015","key":"2021122508150253600_onco12126-bib-0036"},{"key":"2021122508150253600_onco12126-bib-0037","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2147\/TCRM.S2780","article-title":"Cost-effectiveness analysis of electrochemotherapy with the Cliniporatortrade mark vs other methods for the control and treatment of cutaneous and subcutaneous tumors","volume":"4","author":"Colombo","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"2021122508150253600_onco12126-bib-0038","first-page":"785","article-title":"Descriptive study of the costs of diagnosis and treatment of cutaneous melanoma [in Spanish]","volume":"100","author":"Almazan-Fernandez","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"2021122508150253600_onco12126-bib-0039","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1472-6963-14-163","article-title":"The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer","volume":"14","author":"Koerber","year":"2014","journal-title":"BMC Health Serv Res"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0040"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0041"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0042"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0043"},{"year":"2016","key":"2021122508150253600_onco12126-bib-0044"},{"year":"2012","key":"2021122508150253600_onco12126-bib-0045"},{"year":"2012","key":"2021122508150253600_onco12126-bib-0046"},{"year":"2012","key":"2021122508150253600_onco12126-bib-0047"},{"year":"2017","author":"Ascierto","key":"2021122508150253600_onco12126-bib-0048"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0272","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/8\/951\/41914453\/oncolo_22_8_951.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/8\/951\/41914453\/oncolo_22_8_951.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:15:54Z","timestamp":1640420154000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/8\/951\/6444427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,5,19]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0272","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2017,8,1]]},"published":{"date-parts":[[2017,5,19]]}}}